Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» risankizumab
risankizumab
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Motley Fool
Sun, 05/19/19 - 04:05 pm
Alexion
Ultomiris
AbbVie
Upadacitinib
risankizumab
Aimmune Therapeutics
AR-101
Bluebird Bio
LentiGlobin
Go or no go? Abbvie, Glaxo and Heron await FDA verdicts
EP Vantage
Thu, 03/28/19 - 10:18 am
FDA
AbbVie
Heron Therapeutics
HTX-011
GSK
dolutegravir/lamivudine
risankizumab
Gimoti
Evoke Pharma
AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
Endpoints
Wed, 03/27/19 - 10:19 am
AbbVie
Japan
psoriasis
risankizumab
Skyrizi
2 Things Investors Are Missing About AbbVie
Motley Fool
Sun, 03/17/19 - 01:29 pm
AbbVie
ABBV-599
Humira
risankizumab
upadacatinib
Imbruvica
Venclexta
Orilissa
Forget Humira -- Here's What You Need to Know About AbbVie
Motley Fool
Sun, 01/27/19 - 12:13 pm
AbbVie
Humira
Upadacitinib
risankizumab
Rick Gonzalez
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
CP Wire
Tue, 05/1/18 - 09:25 pm
AbbVie
EMA
Europe
risankizumab
psoriasis
AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis
Tue, 05/1/18 - 10:08 am
AbbVie
psoriasis
risankizumab
These 3 Drugs Are Critical to AbbVie's Success
Motley Fool
Mon, 02/12/18 - 09:10 am
AbbVie
Rova-T
Upadacitinib
risankizumab
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
Market Realist
Thu, 02/8/18 - 11:17 am
AbbVie
R&D
immunology
Upadacitinib
risankizumab
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst
Fierce Pharma
Wed, 12/6/17 - 09:53 am
AbbVie
psoriasis
risankizumab
JNJ
Tremfya
AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment
Marketwatch
Mon, 12/4/17 - 09:48 am
AbbVie
psoriasis
risankizumab
clinical trials
AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition
Endpoints
Thu, 10/26/17 - 09:28 am
AbbVie
psoriasis
risankizumab
Humira
Stelara
clinical trials
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
Tue, 10/3/17 - 11:50 am
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
3 Biggest Risks for AbbVie in 2017
Motley Fool
Wed, 12/28/16 - 11:03 am
AbbVie
Humira
biosimilars
Imbruvica
Viekira Pak
Elagolix
risankizumab
How AbbVie Expects Risankizumab to Be a Transformative Therapy
Market Realist
Wed, 08/24/16 - 10:40 am
AbbVie
risankizumab
Crohn's Disease
AbbVie’s Newly Licensed Drug Scores Against Crohn’s Disease
Investors.com
Tue, 05/24/16 - 11:54 pm
AbbVie
Crohn's Disease
risankizumab
Boehringer Ingelheim